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Abstract
Background: There are considerable phenotypic and neuroimmune overlaps between myalgic encephalomyelitis/
chronic fatigue syndrome (ME/CFS) and multiple sclerosis (MS). While the precise aetiologies of both MS and ME/
CFS are unclear, evidence suggests that deterioration in cognitive function is widely prevalent in patients with
either condition. Little is known about differing risk factors or exposures, which may lead to severe cognitive or
sleep symptoms. This study aims to gauge the extent of cognitive and sleep symptoms in ME/CFS and MS patients
participating in the UK ME/CFS Biobank and identify the characteristics of those experiencing severe symptoms.
Methods: This was a cross-sectional study of 395 UK ME/CFS Biobank participants, recruited from primary care and the
community, using similar standardised protocols, and matched by age, sex and geographical area. Data were collected
from participants using a standardized written questionnaire at clinical visits. Cognitive symptoms included problems
with short-term memory, attention, and executive function. Sleep symptoms included unrefreshing sleep and poor
quality or inadequate duration of sleep. All participants reported symptoms based on an ordinal severity scale.
Multivariable logistic regression was carried out in the ME/CFS group to investigate socio-demographic factors
associated with severe symptoms.
Results: All cognitive and sleep symptoms were more prevalent in the ME/CFS group, with ‘trouble concentrating’
(98.3%) the most commonly reported symptom. Severe symptoms were also more commonly reported in the ME/CFS
group, with 55% reporting ‘severe, unrefreshing sleep’. Similarly, in the MS group, the most commonly reported severe
symptoms were sleep-related. Logistic regression analysis revealed that ME/CFS patients aged over 50 years were more
than three times as likely to experience severe symptoms than those younger than 30 (OR 3.23, p = 0.031). Current
smoking was associated with severe symptoms, increasing the risk by approximately three times (OR 2.93, p = 0.003)
and those with household incomes of more than £15,000 per year were less likely to experience severe symptoms
compared to those earning less than this (OR 0.31, p = 0.017).
Conclusions: Cognitive and sleep symptoms are more common in ME/CFS patients than in MS patients and healthy
controls, providing further support for existing evidence of central nervous system abnormalities in ME/CFS. Our
findings suggest that people with ME/CFS who are smokers, or have a low income, are more likely to report severe
cognitive and sleep symptoms. Future research should aim to develop strategies to prevent the progression of severe
cognitive and sleep symptoms through early interventions that prioritise patients identified as being at highest risk.
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Background
Myalgic encephalomyelitis/chronic fatigue syndrome
(ME/CFS) and multiple sclerosis (MS) are chronic neuro-
logical disorders characterised by a number of symptoms
including debilitating fatigue and cognitive decline [1, 2].
Some authors have proposed that ME/CFS and MS may
share common aetiological and pathophysiological mecha-
nisms [3–7]. While the precise aetiologies of both MS and
ME/CFS are unclear, evidence suggests that changes in
cognitive function are a core component of the conditions
[8, 9]. Cognitive dysfunction has an impact on everyday
life and reduces perceived quality of life [10] and includes
problems with short-term memory, concentration, atten-
tion, and processing, which often coincide with sleep
symptoms. Sleep disturbance is commonly reported, and
may have an impact on non-cognitive symptoms such as
fatigue, in both ME/CFS and MS [11, 12].
There are considerable phenotypic and neuroimmune
overlaps between ME/CFS and MS [5, 13]. The patho-
physiological process underlying changes in cognitive
function in MS relates to the development of plaques
affecting the myelin sheath and therefore axonal transmis-
sion [9]. The underlying process leading to cognitive
changes in ME/CFS is not known, but inflammatory oxi-
dative and nitrosative stress pathways may play a role [14].
A recent appraisal highlighted an increasing body of lit-
erature evidencing neurocognitive impairment in people
with ME/CFS [1]. The authors acknowledged that despite
the lack of evidence on objective changes in sleep archi-
tecture, unrefreshing sleep is omnipresent among those
patients [1]. Thus, further insight into the severity of cog-
nitive features in ME/CFS and MS will improve future
diagnosis, case stratification, and management of these
conditions.
Little is known about socio-demographic, behavioural
and other exposures that may lead to severe cognitive
and sleep symptoms, apart from potential links with
life stress, which have been reported in distinct
diseases [15, 16]. Consequently, Identifying risk
factors for severe cognitive and sleep problems may
aid in the development of methods to limit or pre-
vent such debilitating symptoms.
This study aims to ascertain the prevalence of severe
cognitive and sleep symptoms, and factors increasing the
likelihood of reporting severe symptoms, in healthy
controls and people with ME/CFS and MS participating
in the UK ME/CFS Biobank.
Methods
Population and size
This was an analytical cross-sectional study with disease
and control groups, who were recruited to the UK ME/
CFS Biobank [17]. Of 395 participants, 237 had been di-
agnosed with ME/CFS, 47 with MS, and 111 were
healthy controls. This sample size is adequate to identify
prevalence differences of symptoms between people with
ME/CFS or MS and healthy controls, with a power of
98% and of 91% respectively at a 0.05 significance level.
This is based on a conservative prevalence of 3% for
cognitive symptoms, among the general population [18].
The power calculation was performed with Epi Info 7™
[19]. The UK ME/CFS Biobank participants were
recruited from those with a medically confirmed diagno-
sis of ME/CFS from National Health Services (NHS) in
London, East Anglia and other parts of the UK, covered
by the Clinical Research Network and Primary Care
Network (CRN/PCN), local divisions and the ME/CFS
pilot Disease Register (DR). A few severely affected partici-
pants were also recruited from support groups and patient
associations. Healthy controls were frequency matched to
cases by gender, geographical area of residence, and age
within five years of cases. Healthy controls were
excluded if they had previous or current chronic
fatiguing disease, such as cardiomyopathy or cancer.
Healthy controls were recruited through the PCN,
invited by people with ME/CFS, or responded to
adverts in the same areas of recruitment. MS patients
were recruited from collaborating GP practices or
other secondary care health services, particularly
those in the CRN/PCN located in the same region as
the ME/CFS cases. Standardised procedures, including
inclusion and exclusion criteria and bespoke question-
naires applied to all consenting UK ME/CFS partici-
pants, are described in detail elsewhere [20].
Inclusion and exclusion criteria
All participants, who were aged 18 to 60 years old, gave
informed consent for study participation. ME/CFS cases
were selected if they had a clinical diagnosis of ME/CFS
according to the Centers for Disease Control and Preven-
tion (CDC) [21] or Canadian Consensus Criteria (CCC)
[8]. Disease status was confirmed by a clinical researcher,
who reviewed laboratory test results to exclude alternative
diagnoses. All MS cases had a diagnosis confirmed by a
NHS neurologist, in compliance with the National Insti-
tute for Clinical Excellence (NICE) guidelines [22]. Infor-
mation on specific type of MS was not routinely collected,
but those on immunomodulatory drugs, were excluded
due to the potential effects of these factors on disease pro-
cesses and therefore reported symptoms. People with a
diagnosis of MS were excluded if they had any other
conditions apart from MS that could explain their fatigue
including pregnancy or lactation.
Data collection
Data were collected from all participants using self-
completed questionnaires including validated instruments.
Others were developed specifically for the recruitment of
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participants to the UK ME/CFS Biobank, to complement
the clinical assessment, which included physical examin-
ation and blood collection. Data collection ran from
March 2012 to December 2015 and consisted of demo-
graphic and socio-economic data and a range of exposure
variables and symptoms. Socio-demographic details col-
lected included age, gender, ethnicity, household income,
and education. Lifestyle variables included smoking and
drinking habits. Symptom assessments asked about cogni-
tive, sleep, musculoskeletal, cardiovascular, autonomic,
and systemic symptoms in the week prior to participant
questionnaire. Co-morbidities and family health history
were also recorded. The results presented in this paper
focus on cognitive and sleep symptoms.
Statistical analysis
Data were analysed using STATA 14 [23]. Cognitive symp-
toms analysed included problems with short-term mem-
ory, attention, and executive function; sleep disturbance
was also recorded. Symptoms were analysed based on an
ordinal severity scale (absent, mild, moderate, or severe)
for three groups: ME/CFS, MS, and healthy controls. The
prevalence of such symptoms in each group is displayed
by severity. Chi-squared test was used in simple univariate
analyses to compare non-continuous variables. Trends for
statistical significance between symptoms across patient
groups were tested with the χ2 test for trend and the likeli-
hood ratio test, considering “severity” as an ordered
categorical variable [24]. A cut-off of 0.05 was used for the
probability of alpha-1 error to indicate significance of an
association.
Various factors were investigated for potential associa-
tions with severe cognitive and sleep symptoms in ME/
CFS and MS. For the ME/CFS multivariable logistic
regression model, all variables were analysed through uni-
variate logistic regression and only included in the multi-
variable model if statistically significant or if considered to
be clinically important. For MS, univariate logistic regres-
sion was used to investigate factors associated with severe
cognitive and sleep symptoms because the small sample
size precluded the use of a multivariable model.
Socio-demographic variables such as age and income
were included in the final model because of a possible
association between such factors and cognitive function
[25, 26]. The low numbers of ethnic minority participants
led to grouping of non-white ethnicities before comparing
with white participants. Alcohol consumption six months
before symptoms appeared in participants with ME/CFS or
MS was classified as “no drinking” or “<14 units/week and
≥14 units/week”. This cut-off of 14 units/week was chosen
because it is the current guideline for maximum weekly
consumption recommended by the UK Department of
Health [27]. Smoking status compared non-smokers to ex-
smokers and current smokers. Other factors investigated in
the initial univariate regression models included lifestyle
factors such reported stress and activity levels as well as
medical factors such as depression, anxiety, allergy, infec-
tion, asthma, and surgery in the six months before the
questionnaire was completed. In the multivariable models,
variables related to the time of recruitment, except for alco-
hol consumption and depression, which were also asked
about six months previous to symptoms appearance. As
duration of fatigue may have had an effect on the reported
severity of symptoms, we also included this in the model,
even if the difference was not statistically significant at the
univariate analysis (Wilcoxon rank-sum test was used as
this variable was not normally distributed). To limit the im-
pact of missing data on the regression analysis, an assump-
tion was made that any missing data for a specific variable
corresponded to a “negative answer” or absence of the par-
ticular risk factor, providing a conservative estimate of the
odds ratio. Missing data, although rare, was slightly higher
in those with ME/CFS (1.42 per variable/100-persons) than
those with MS (0.39 per variable/100 persons), and in
healthy controls (0.25 per variable/100 persons).
The main dependent variable for the logistic regres-
sion analysis was a symptom severity score. This was
calculated through an ordinal severity scale, with no
points if the symptom was not reported, one point for a
symptom reported as mild, two for moderate, and three
for severe. An aggregate score (out of 27) for the severity
of the nine individual cognitive and sleep symptoms was
then calculated for each patient. Scores above the 75th
centile for the ME/CFS group (21/27) and the MS group
(14/27) were considered to be severe for each group
respectively. Logistic regression was then used to investi-
gate factors associated with severe cognitive and sleep
symptoms in each of ME/CFS and MS groups by
comparing those with scores equal to or above the 75th
centile with those scores below it.
Results
In the overall study population, 289 (73.2%) were female
and 106 (26.8%) male. The median age was 44 years, with
an interquartile range of 35 to 53 years. Three hundred
and sixty-one participants (91.4%) identified themselves as
white British, and 104 (28.3%) reported an income less
than £15.000 a year at the time of data collection. Socio-
demographic details of the study population are illustrated
by group (Table 1).
Table 2 displays the prevalence of cognitive and sleep
symptoms over the previous week as reported by each
group, by severity. All symptoms were more prevalent in
the ME/CFS group, with ‘trouble concentrating’ the most
commonly reported symptom in this group, at 98.3%. The
remaining cognitive and sleep symptoms were common at
over 80% for all except disorientation, which was reported
by 56.5% of the ME/CFS group. Although not as frequent
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as in ME/CFS, cognitive and sleep symptoms were widely
reported in MS patients, with the most commonly
reported symptoms being unrefreshing sleep (78.7%),
trouble concentrating (74.5%), problems with sleep quality
or duration (72.3%), and short-term memory problems
(72.3%). Healthy controls reported very few symptoms.
Severe symptoms were more commonly reported in the
ME/CFS group, most notably unrefreshing sleep (55.3%)
and poor quality or short duration of sleep (41.8%). Simi-
larly, in the MS group the most commonly reported
severe symptom was unrefreshing sleep (27.7%). The
number of MS patients reporting severe non-sleep related
symptoms was low ranging from 2.1 to 6.4%, compared
with the ME/CFS group where it ranged from 13.1 to
31.6%. We have compared the duration of fatigue between
people with ME/CFS (median = 11.1 years; Inter Quartile
Range (IQR) 5.9 to 17.6), and people with MS (me-
dian = 10.7 years; IQR = 6.4 to 19.3), using a non-
parametric test and the difference was not significant
(p = 0.688).
Logistic regression analysis
Table 3 displays the results from the multivariable logis-
tic regression model of the factors affecting severity of
cognitive and sleep symptoms in ME/CFS patients. No
clear trend could be observed between increasing age
and symptom severity, although patients aged over 50
were more than three times more likely to experience
severe cognitive and sleep symptoms compared with
those less than 30 years old (OR 3.23, p = 0.031).
Current smoking increased the risk of severe cognitive
and sleep symptoms by approximately three times (OR
2.93, p = 0.003) and ex-smokers were more than twice
as likely to experience symptoms compared with non-
smokers (OR 2.17, p = 0.034). People with household in-
comes of £15,000 or more per year were approximately
70% less likely to report severe symptoms compared to
those earning less than this (OR 0.31, p = 0.017). There
were no statistically significant associations between
gender, ethnicity or depression and severe cognitive and
sleep symptoms in ME/CFS.
Table 4 shows logistic regression analysis results for
the factors affecting severity of cognitive and sleep symp-
toms in patients with MS. The only variable significantly
associated with severe symptoms in MS was previous
depression. MS patients who experienced depression prior
to symptoms were over seven times more likely to report
severe symptoms (p = 0.009). Socio-demographic variables
including age, gender, ethnicity, income, smoking, and
alcohol consumption were not associated with severe cog-
nitive and sleep symptoms in MS.
Discussion
Key findings
Cognitive and sleep symptoms were more common in
ME/CFS patients than in MS patients and healthy
controls. The number of participants reporting severe
symptoms was also highest in the ME/CFS group. The
most commonly reported severe symptom in both groups
was unrefreshing sleep: 55.3% in the ME/CFS group, com-
pared with 27.7% in the MS group. The number of MS pa-
tients reporting severe non-sleep related symptoms was
relatively low (ranging from 2.1 to 6.4%), compared with
the ME/CFS group (ranging from 13.1 to 31.6%).
In the ME/CFS patients, multivariable logistic regression
revealed that the severe cognitive and sleep symptoms were
associated and increased with previous and current smok-
ing as well as with low income (<£15,000). Although there
was no consistently significant trend with age, those over
50 years were more likely to experience severe symptoms
compared with those less than 30 years old. In the MS
group, univariate logistic regression demonstrated that pre-
vious depression was associated with a higher likelihood of
patients reporting severe cognitive and sleep symptoms.
Prevalence of severe cognitive and sleep symptoms
The Canadian Consensus document [8] states that cog-
nitive symptoms including confusion, slowed processing
Table 1 Characteristics of study population, by group
Variables Categories ME/CFS
n (%)
MS
n (%)
Healthy
Control n (%)
Gender Male 54 (22.8) 13 (27.7) 39 (35.1)
Female 183 (77.2) 34 (72.3) 72 (64.9)
Age group <30 40 (16.9) 0 18 (16.2)
30–39 48 (20.3) 9 (19.1) 24 (21.6)
40–49 65 (27.4) 15 (31.9) 30 (27.0)
50+ 84 (35.4) 23 (48.9) 39 (35.1)
Ethnicity White British 220 (92.3) 45 (95.7) 96 (86.5)
White Other 5 (2.11) 2 (4.26) 6 (5.41)
Black African 1 (0.42) 0 1 (0.90)
Asian 2 (0.84) 0 4 (3.60)
Other 7 (2.95) 0 4 (3.60)
Income <£15,000 71 (32.3) 10 (24.4) 23 (21.5)
> = £15,000 149 (67.7) 31 (75.6) 84 (78.5)
Alcohol intakea No Alcohol 87 (36.7) 9 (19.15) 25 (22.5)
<14 units/week 118 (49.8) 27 (57.4) 69 (62.1)
≥14 units/week 32 (13.5) 11 (23.4) 17 (15.3)
Smoking status Never Smoked 150 (63,2) 19 (40.4) 78 (70.2)
Ex-smoker 62 (26.1) 15 (31.9) 0
Current Smoker 25 (10.5) 13 (27.7) 33 (29.8)
Depressiona No depression 143 (60.3) 36 (81.8) 111 (100)
Depression 94 (39.7) 11 (23.4) 0
aSix months before symptoms for ME/CFS or MS (or at recruitment for
healthy controls)
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Table 2 Severity of cognitive and sleep symptoms over past week, by group
Symptom over past week Severity ME/CFS n/total = 237 (%) MS n/total = 47 (%) Healthy control n/total = 111 (%) P-value*
Poor sleep quality/duration <0.001
Absent 26 (10.9) 14 (29.8) 70 (63.1)
Mild 31 (13.1) 15 (31.9) 26 (23.4)
Moderate 81 (34.2) 10 (21.3) 13 (11.7)
Severe 99 (41.8) 8 (17.0) 2 (1.8)
Unrefreshing sleep <0.001
Absent 11 (4.6) 10 (21.3) 64 (57.7)
Mild 22 (9.3) 12 (25.5) 34 (30.6)
Moderate 73 (30.8) 12 (25.5) 11 (9.9)
Severe 131 (55.3) 13 (27.7) 2 (1.8)
Difficulty retaining information <0.001
Absent 21 (8.9) 16 (34.0) 93 (83.8)
Mild 70 (29.5) 17 (36.2) 18 (16.2)
Moderate 83 (35.0) 11 (23.4) 0
Severe 63 (26.6) 3 (6.4) 0
Difficulty understanding/thinking clearly <0.001
Absent 27 (11.4) 23 (48.9) 97 (87.4)
Mild 77 (32.5) 12 (25.5) 14 (12.6)
Moderate 76 (32.1) 9 (19.1) 0
Severe 57 (24.1) 3 (6.4) 0
Slow thinking <0.001
Absent 34 (14.3) 19 (40.4) 97 (87.4)
Mild 77 (32.5) 14 (29.8) 14 (12.6)
Moderate 80 (33.8) 11 (23.4) 0
Severe 46 (19.4) 3 (6.4) 0
Disorientation <0.001
Absent 107 (45.1) 31 (66.0) 107 (96.4)
Mild 51 (21.5) 9 (19.1) 3 (2.7)
Moderate 48 (20.3) 6 (12.8) 1 (0.9)
Severe 31 (13.1) 1 (2.1) 0
Trouble concentrating <0.001
Absent 6 (2.5) 12 (25.5) 84 (75.7)
Mild 54 (22.8) 15 (31.9) 23 (20.7)
Moderate 102 (43.0) 18 (38.3) 3 (2.7)
Severe 75 (31.6) 2 (4.3) 1 (0.9)
Short term memory problems <0.001
Absent 22 (9.3) 13 (27.7) 90 (81.1)
Mild 65 (27.4) 17 (36.2) 19 (17.1)
Moderate 91 (38.4) 15 (31.9) 2 (1.8)
Severe 59 (24.9) 2 (4.3) 0
Brain fog/confusion <0.001
Absent 38 (16.0) 21 (44.7) 99 (89.2)
Mild 62 (26.2) 9 (19.1) 11 (9.9)
Moderate 77 (32.5) 15 (31.9) 1 (0.9)
Severe 60 (25.3) 2 (4.3) 0
Missing data entered as ‘absence of symptoms’ for all groups
* χ2 test for trend
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of information, difficulty concentrating, poor short-term
memory, and sleep problems are common in ME/CFS.
Fukuda et al. [28] propose that apart from fatigue and
musculoskeletal pain, the most prominent features of
ME/CFS are impairments in concentration, short-term
memory, and sleep disturbances. Recently, the Institute
of Medicine reviewed the evidence on the major
symptoms of ME/CFS and reiterated that cognitive
symptoms, sleep related symptoms and primary sleep
disorders are common features [1]. Our study provides
an empirical estimation of the proportion of ME/CFS
patients affected by cognitive symptoms, with all symp-
toms except disorientation being reported in more than
80% of ME/CFS patients. We also found that the classic
Table 3 Multivariable Analysis: Factors related to prevalence of severe cognitive and sleep symptoms in ME/CFS
Variable Odds ratio 95% Confidence interval p value
Age < 30 1.00 - 0.204
Age 30–39 2.30 0.69–7.66
Age 40–49 2.34 0.73–7.56
Age 50+ 3.23 1.04–10.04
Male 1.00 - 0.138
Female 1.88 0.81–4.30
Non-white ethnicity 1.00 - 0.521
White ethnicity 0.65 0.18–2.39
Income < £15,000 1.00 - 0.017
Income > = £15,000 0.31 0.12–0.81
No alcohol (six months before) 1.00 - 0.942
Alcohol <14 units/week (six months before disease onset) 0.96 0.48–1.94
Alcohol ≥14 units/week (six months before disease onset) 1.15 0.40–3.30
No smoking 1.00 - 0.026
Ex-smoker 2.17 1.06–4.42
Current smoker 2.93 1.11–7.70
No depression before symptoms 1.00 - 0.169
Depression before symptoms 1.58 0.82–3.03
Duration of fatigue (years) 0.99 0.94–1.05 0.804
Table 4 Univariate analysis: factors related to the prevalence of severe cognitive and sleep symptoms in MS
Variable Odds Ratio 95% confidence interval p value
Age < 30 1.00 - 0.731
Age 30–39 0.94 0.18–4.79
Age 40+ 0.47 0.10–2.16
Male 1.00 - 0.424
Female 0.58 0.15–2.23
Income < £15,000 1.00 - 0.756
Income > = £15,000 0.67 0.05–8.64
No alcohol (six months before) 1.00 - 0.21
Alcohol <14 units/week (six months before disease onset) 0.53 0.11–2.49
Alcohol ≥14 units/week (six months before disease onset) 0.28 0.04–2.09
No smoking 1.00 - 0.93
Ex-smoker 0.79 0.18–3.53
Current smoker 0.96 0.21–4.42
No depression before symptoms 1.00 - 0.009
Depression before symptoms 7.25 1.65–31.8
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ME/CFS symptoms of sleep disturbance and trouble
concentrating were most commonly reported as severe
compared to other symptoms.
Unrefreshing sleep, or sleep of poor quality or short dur-
ation were the most commonly reported severe symptoms
in both the ME/CFS and MS groups. Krupp et al. evalu-
ated the sleep characteristics in 72 patients with ME/CFS
compared with 57 MS patients [11] and found that the
ME/CFS patients experienced significantly more sleep dis-
turbance compared with MS patients. Among the ME/
CFS patients, 37% reported light sleeping, 15% reported
inadequate sleep, and 27% reported early waking, com-
pared with 10, 5, and 0% respectively for the MS group.
The findings of our study are consistent with rates were
higher for ME/CFS participants, although sleep distur-
bances were common in both groups.
Guidelines for ME/CFS participant (Fukuda criteria)
study inclusion advise excluding those with primary
sleep disorders. Unrefreshing sleep is the only ME/
CFS criteria relating to sleep in the Fukuda guidelines
[28]. However, other authors argue that primary sleep
disorders should be treated as co-morbidities, and
their presence should not preclude a diagnosis of
ME/CFS [1]. In people with ME/CFS, no consistent
abnormal sleep pattern has been found on polysom-
nography [29] adding to the difficulty in treating sleep
disturbances. Nevertheless, the emergence of new,
more sensitive techniques suggest that alterations in
sleep stage transitions and other physiological mecha-
nisms, such as heart rate variability and cortisol
profiles, may be evident in ME/CFS. A 2013 cross-
sectional study of 343 ME/CFS patients [29] described
four sleep-specific phenotypes, with objective diffe-
rences among them in sleep onset latencies as well as
rapid eye movement (REM) stages and latencies. The
high prevalence of severe sleep symptoms reported in
our study indicates that data characterising distinct
sleep patterns could prove vital in identifying targeted
methods for treatment in ME/CFS patients.
Risk factors for severe cognitive and sleep symptoms
Our study is unique in exploring risk factors for cognitive
and sleep symptoms and their severity in ME/CFS. A 2008
systematic review of eleven case-control, cohort, and
cross-sectional studies assessed various potential factors
correlated with the development of ME/CFS, but causal
evidence is lacking [30]. Factors found to be significantly
associated with the development of ME/CFS, which our
study also investigated, were older age [31, 32], being
female [32, 33], the presence of an anxiety disorder [31],
mood disorder [34] or stress [35], and a history of allergies
or asthma [36]. Based on our findings, the majority of
these factors do not appear to translate from risk of deve-
lopment of ME/CFS to risk of severe cognitive and sleep
symptoms in ME/CFS. That said, ME/CFS patients over
the age of 50 were more than three times more likely to
experience severe cognitive and sleep symptoms, com-
pared to those under age 30. The reason for older age
causing more severe symptoms are complex, but may be
at least partially due to age-related decreases in brain
dopamine activity contributing to impaired performance
on tasks that involve frontal brain regions [37]. The
pathophysiological processes occurring in ME/CFS may
exaggerate normal age-related processes. For instance,
Xenon-computed tomography blood flow studies show
significantly lower cortical/cerebellar regional cerebral
blood flow (rCBF) in ME/CFS [38].
A cross-sectional population-based US study (n = 5623)
found that income was not related to the prevalence of
ME/CFS in the general population [39]. However, our ana-
lysis found that ME/CFS participants with household in-
comes of under £15,000 per year were at an increased risk
of severe cognitive and sleep symptoms. Although there
scant literature exploring the effect of income on severity
of symptoms in ME/CFS, a 1995 cohort study [40] of 49
patients found that environmental and psychosocial
stressors exacerbated self-reported ME/CFS symptoms
following a natural disaster. It is plausible that such
stressors may play a similar role in the daily lives of indi-
viduals with lower incomes. In addition, existing literature
describes an association between relative poverty and
sleep symptoms in healthy individuals [41]. However,
more evidence is required to explore the possible associ-
ation between low income and severity of cognitive symp-
toms in ME/CFS, and the precise mechanism of this
relationship.
Smoking was also found to be associated with severe
cognitive and sleep symptoms. Previous evidence from a
large multicentre cohort study (EURODEM), with 9209
non-demented patients selected for follow-up, found
that smoking leads to cognitive decline [42]. The mini-
mental state exam (MMSE) of those who never smoked
declined by 0.03 points/year. The decline in score for
previous smokers was 0.03 points greater than this, and
for current smokers was 0.13 points greater than never
smokers (p < 0.001). The results of our study concur with
such evidence, finding a relationship between smoking
habits and severe cognitive and sleep symptoms in ME/
CFS. This is of clinical importance as it suggests that stop-
ping or preventing smoking may help reduce the risk of
developing more severe symptoms in such patients.
Strengths and limitations
This study included a relatively large sample size of ME/
CFS participants (n = 237), a healthy control group, and
participants with another neurological disease for
comparison. This enabled a reliable statistical analysis of
predictive factors for people with severe symptoms of
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ME/CFS. The study population included participants
from multiple sites across the UK and with varying
degrees of severity, so although our results may not be
generalizable to the entire UK population, they are
reflective of a wide range of participants rather than a
particular subset. All data were collected in a standar-
dized form and all participants had contact with the
clinical team for assessment, optimizing data reliability.
Finally, data were gathered on a broad range of socio-
demographic variables, exposures, and symptoms. For
this reason, we have been able to explore the prevalence
of cognitive and sleep symptoms between different dis-
ease groups and investigate numerous predictive factors.
The main limitation of the study lies in the relatively
low number of participants with MS (n = 47), restricting
our ability to conduct multivariable analysis in this
group. Nonetheless, univariate regression analysis was
used to explore potentially associated factors of clinical
importance, but these will require validation in studies
with larger sample sizes. In addition, information on
specific type of MS was not routinely collected, and
therefore we were not able to ascertain differences be-
tween distinct MS subtypes. In the overall study popula-
tion, most of the participants recruited identified
themselves as being of white British ethnicity (n = 391),
restricting the generalizability of results to the wider
multi-ethnic population. Although our analysis included
severely-affected participants there may have been some
people with ME/CFS who were so ill, for example on
nasogastric feeding, that they could not participate in
the study. Additional limitations inherent to the study
design and data collection methods are recognized and
have to be taken into account when considering our
findings, such as the possibility of residual confounding.
The cross-sectional nature of the data, even with a
control group, can be indicative of associations, but not
causality. Additionally, recall bias is also an issue to be
considered in self-reported data collection. However, the
consistency of responses across the three groups indi-
cates that this bias is unlikely to have been significant.
Implications for clinical practice and future research
In MS patients, a history of depression was found to be
associated with severe cognitive and sleep symptoms.
Depression is common in MS [43] and is thought to
interfere with cognitive function. Arnett et al. [44]
conducted a critical review of the existing literature on
depression in MS, to find that a positive link has been
consistently noted between depression and cognitive
functioning. Depression affects many aspects of cogni-
tive functioning in MS, including working memory, pro-
cessing speed, and executive functioning [45–47]. Our
findings therefore support existing evidence, and suggest
that efforts aiming to treat or prevent depression could
lead to improvements in the reported severity of cogni-
tive symptoms in patients with MS.
The high prevalence of cognitive and sleep symptoms
in ME/CFS highlights the need for improved strategies
to combat their effects. Unlike MS, the severity of these
symptoms seems to be unrelated to depression, and
might reflect more generalised and subtle abnormalities
in the CNS. Unrefreshing sleep was the most commonly
reported severe symptom. Research has demonstrated
that sleep physiology is altered in ME/CFS patients [48],
but management of the condition, and available pharma-
cological therapy, still fails to address this critical issue.
Future research must explore both pharmacological and
non-pharmacological methods aimed at improving quality
and duration of sleep in ME/CFS.
In clinical practice, patients may be advised of the
various factors that can lead to severe cognitive and
sleep symptoms. To recommend smoking cessation is a
general public health measure that can be reinforced,
and prevention of smoking in those at potential higher
risk of ME/CFS, such as those with prolonged fatigue
following an infectious disease, is important to reduce
risk of severe cognitive and sleep symptoms. Public
health and medical interventions to improve symptoms
must recognise that those with a low-income (≤£15,000)
seem to be at a higher risk of developing severe symptoms.
Despite the relatively high prevalence of cognitive
impairment in MS, cognitive function is not assessed
routinely in clinical practice or in clinical trials [49]. Our
findings suggest that sleep problems, rather than other
cognitive problems, are severe in a large minority of MS
patients. The perception that cognitive assessments are
costly, time-consuming and difficult to interpret has
contributed to the failure to incorporate cognitive test-
ing into standard clinical evaluation of patients with MS.
Detailed studies of cognitive impairment in MS are rare,
and guidelines for the assessment of cognitive or sleep
function in MS are lacking. Future research must
address these gaps in the current knowledge base.
Researchers may find it beneficial to incorporate cogni-
tive and sleep function measures into clinical assessment
of MS and ME/CFS, and encourage the development of
novel therapies targeting such symptoms.
Conclusions
Cognitive and sleep symptoms were more common in
people with ME/CFS in this study than in both healthy
controls and people with MS. This provides further
support for existing evidence of central nervous system
abnormalities in ME/CFS and highlights the need for
improved strategies to address the effects of such symp-
toms. Unrefreshing sleep was the most commonly re-
ported severe symptom in both people with ME/CFS
and people with MS, although it was more prevalent in
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those with ME/CFS. Our findings suggest that people with
ME/CFS who are smokers, or have a low income, are more
likely to report severe cognitive and sleep symptoms. Fu-
ture research should aim to develop strategies to prevent
the progression of severe cognitive and sleep symptoms
through early interventions that prioritise patients identi-
fied as being at highest risk.
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